What is the Market's View on Rigel Pharmaceuticals Inc (RIGL) Stock's Price and Volume Trends Monday?

The market has been down on Rigel Pharmaceuticals Inc (RIGL) stock recently. RIGL gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Rigel Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RIGL!

See Full RIGL Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With RIGL Stock Today?

Rigel Pharmaceuticals Inc (RIGL) stock is trading at $1.49 as of 10:30 AM on Monday, Mar 20, a gain of $0.02, or 1.71% from the previous closing price of $1.46. The stock has traded between $1.43 and $1.49 so far today. Volume today is light. So far 446,536 shares have traded compared to average volume of 3,776,333 shares. To screen for more stocks like Rigel Pharmaceuticals Inc click here.

More About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. Click Here to get the full Stock Report for Rigel Pharmaceuticals Inc stock.